Borse V, Konwar AN, Buragohain P (2020) Oral cancer diagnosis and perspectives in India. Sens Int 1:100046

Article  PubMed  PubMed Central  Google Scholar 

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26(1):677–704

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benicky J, Sanda M, Kennedy ZB, Grant OC, Woods RJ, Zwart A et al (2021) PD-L1 glycosylation and its impact on binding to clinical antibodies. J Proteome Res 20(1):485–497

Article  CAS  PubMed  Google Scholar 

Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS et al (2015) PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma. Oncotarget 6(39):42067–42080

Article  PubMed  PubMed Central  Google Scholar 

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

Article  PubMed  PubMed Central  Google Scholar 

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res Off J Am Assoc Cancer Res 20(19):5064–5074

Article  CAS  Google Scholar 

Groeger S, Howaldt HP, Raifer H, Gattenloehner S, Chakraborty T, Meyle J (2017) Oral Squamous Carcinoma Cells Express B7–H1 and B7-DC Receptors in Vivo. Pathol Oncol Res POR 23(1):99–110

Article  CAS  PubMed  Google Scholar 

Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT et al (2010) Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol Off J U S Can Acad Pathol Inc 23(10):1393–4035

CAS  Google Scholar 

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS et al (2004) Costimulatory B7–H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101(49):17174–17179

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19–24

Article  PubMed  Google Scholar 

Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J et al (2014) B7–H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer. Int J Clin Exp Pathol 7(9):6015–6023

PubMed  PubMed Central  Google Scholar 

Viechtbauer W, Smits L, Kotz D, Budé L, Spigt M, Serroyen J et al (2015) A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol 68(11):1375–1379

Article  PubMed  Google Scholar 

Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A et al (2018) Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. J Ovarian Res 11(1):43

Article  PubMed  PubMed Central  Google Scholar 

Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306

Article  CAS  PubMed  Google Scholar 

Yagyuu T, Hatakeyama K, Imada M, Kurihara M, Matsusue Y, Yamamoto K et al (2017) Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Oral Oncol 68:36–43

Article  CAS  PubMed  Google Scholar 

Geum DH, Hwang DS, Lee CH, Cho SD, Jang MA, Ryu MH et al (2022) PD-L1 expression correlated with clinicopathological factors and Akt/Stat3 pathway in oral SCC. Life 12(2):238

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM et al (2015) High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One 10(11):e0142656

Article  PubMed  PubMed Central  Google Scholar 

Cui YX, Su XS (2020) Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. Open Med 15(1):292–301

Article  CAS  Google Scholar 

Srinivasalu VK, Subramaniam N, Iyer S, Nambiar A, Koyakutty M, Thankappan K et al (2019) PDL-1 expression in oral squamous cell carcinoma and implications for treatment. J Glob Oncol 5(suppl):82–82

Article  Google Scholar 

Takamaru N, Fukuda N, Akita K, Kudoh K, Miyamoto Y (2022) Association of PD-L1 and ZEB-1 expression patterns with clinicopathological characteristics and prognosis in oral squamous cell carcinoma. Oncol Lett 23(3):75

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandini S, Massi D, Mandalà M (2016) PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88–98

Article  PubMed  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454

Article  CAS  PubMed  PubMed Central  Google Scholar